Navigation Links
Aurigene Announces Transition of Multiple Programs to Clinical Development in its Collaboration Business
Date:4/18/2013

BRIDGEWATER, New Jersey, April 18, 2013 /PRNewswire/ --

Aurigene has had a number of collaboration programs with large pharma companies over the years, and has reported successes in these programs.

     (Logo: http://photos.prnewswire.com/prnh/20130418/608115)

Elaborating on the successful collaboration programs, Aurigene's CEO CSN Murthy said "Aurigene combines its excellent execution of integrated drug discovery programs with the deep biological insights and clinical expertise of its pharma partners, and this has resulted in a very efficient model that delivers clinical candidates in timelines of 3 years or less in challenging programs."

One of Aurigene's pharma collaborations, covering 4 different programs in oncology, has seen the company delivering a clinical candidate currently in Ph 1 trials in the hands of its partner. Two other challenging programs, both potentially first-in-class molecules, are in late stages of lead optimization, with the potential to reach clinical development over the next 12-15 months. This represents a high success percentage, delivered in a highly cost-efficient and timely manner.

In another large pharma collaboration, Aurigene has been working in a niche area of inflammatory disorders, and has delivered, within 30 months of the start of the collaboration a very exciting clinical candidate for an unmet medical need. This drug candidate is in late stages of regulatory toxicology studies, and could potentially enter the clinic before the end of the current calendar year, subject to regulatory clearances. "Previous attempts to develop candidates against this target by other companies have resulted in compounds with sub-optimal properties, and could not get beyond initial clinical trials. Aurigene's candidate is the first compound against this target that has the potential to overcome the shortcomings observed in the competitor's compounds," said its Sr. VP, Biology, Subramanya Hosahalli .

About Aurigene

Aurigene is a Biotech focussed on early stage collaborations in integrated discovery partnerships, along with its own pipeline of small molecule and peptide therapeutics built for partnering with pharma companies, in the exciting areas of Cancer Metabolism, Epigenetics, Cancer Immunology and the TH17 pathway. Aurigene, with over 500 scientists in its Indian and Malaysian laboratories, has collaborated with 6 of the top 10 pharma companies, in addition to partnerships with mid-sized pharma companies and Biotechs in the US and Europe. For more information on Aurigene's collaboration business model, and its pipeline, please visit the company's website at http://www.aurigene.com.

Media Contacts:
Mark Ravera , Head of Business Development, USA
Rajshree KT
Head Strategic Alliances, India
pr@aurigene.com
+91-40-4465-7777


'/>"/>
SOURCE Aurigene
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):